Levetiracetam in juvenile myoclonic epilepsy: Long-term efficacy in newly diagnosed adolescents

Alberto Verrotti, Caterina Cerminara, Giangennaro Coppola, Emilio Franzoni, Pasquale Parisi, Paola Iannetti, Paolo Aloisi, Elisabetta Tozzi, Raffaella Cusmai, Federico Vigevano, Francesco Chiarelli, Paolo Curatolo

Research output: Contribution to journalArticle

Abstract

The aim of this study was to evaluate the efficacy and tolerability of levetiracetam (LEV) monotherapy in juvenile myoclonic epilepsy (JME). The study group consisted of 32 patients with epilepsy (20 males, 12 females) with a mean age of 13 years 3 months (SD 7y 11mo) at seizure onset. LEV was administered as the first drug; all patients were followed up at 6 and 12 months. The dose that achieved seizure control ranged from 1000 to 2500mg/daily. At 6-month evaluation: 15 patients were seizure free; 14 patients were responders (>50% reduction in seizures); and three patients had marginal effects (

Original languageEnglish
Pages (from-to)29-32
Number of pages4
JournalDevelopmental Medicine and Child Neurology
Volume50
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

etiracetam
Juvenile Myoclonic Epilepsy
Seizures
Epilepsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neuroscience(all)

Cite this

Verrotti, A., Cerminara, C., Coppola, G., Franzoni, E., Parisi, P., Iannetti, P., ... Curatolo, P. (2008). Levetiracetam in juvenile myoclonic epilepsy: Long-term efficacy in newly diagnosed adolescents. Developmental Medicine and Child Neurology, 50(1), 29-32. https://doi.org/10.1111/j.1469-8749.2007.02009.x

Levetiracetam in juvenile myoclonic epilepsy : Long-term efficacy in newly diagnosed adolescents. / Verrotti, Alberto; Cerminara, Caterina; Coppola, Giangennaro; Franzoni, Emilio; Parisi, Pasquale; Iannetti, Paola; Aloisi, Paolo; Tozzi, Elisabetta; Cusmai, Raffaella; Vigevano, Federico; Chiarelli, Francesco; Curatolo, Paolo.

In: Developmental Medicine and Child Neurology, Vol. 50, No. 1, 01.2008, p. 29-32.

Research output: Contribution to journalArticle

Verrotti, A, Cerminara, C, Coppola, G, Franzoni, E, Parisi, P, Iannetti, P, Aloisi, P, Tozzi, E, Cusmai, R, Vigevano, F, Chiarelli, F & Curatolo, P 2008, 'Levetiracetam in juvenile myoclonic epilepsy: Long-term efficacy in newly diagnosed adolescents', Developmental Medicine and Child Neurology, vol. 50, no. 1, pp. 29-32. https://doi.org/10.1111/j.1469-8749.2007.02009.x
Verrotti, Alberto ; Cerminara, Caterina ; Coppola, Giangennaro ; Franzoni, Emilio ; Parisi, Pasquale ; Iannetti, Paola ; Aloisi, Paolo ; Tozzi, Elisabetta ; Cusmai, Raffaella ; Vigevano, Federico ; Chiarelli, Francesco ; Curatolo, Paolo. / Levetiracetam in juvenile myoclonic epilepsy : Long-term efficacy in newly diagnosed adolescents. In: Developmental Medicine and Child Neurology. 2008 ; Vol. 50, No. 1. pp. 29-32.
@article{812eeb579e31466f96ee8334c13fb329,
title = "Levetiracetam in juvenile myoclonic epilepsy: Long-term efficacy in newly diagnosed adolescents",
abstract = "The aim of this study was to evaluate the efficacy and tolerability of levetiracetam (LEV) monotherapy in juvenile myoclonic epilepsy (JME). The study group consisted of 32 patients with epilepsy (20 males, 12 females) with a mean age of 13 years 3 months (SD 7y 11mo) at seizure onset. LEV was administered as the first drug; all patients were followed up at 6 and 12 months. The dose that achieved seizure control ranged from 1000 to 2500mg/daily. At 6-month evaluation: 15 patients were seizure free; 14 patients were responders (>50{\%} reduction in seizures); and three patients had marginal effects (",
author = "Alberto Verrotti and Caterina Cerminara and Giangennaro Coppola and Emilio Franzoni and Pasquale Parisi and Paola Iannetti and Paolo Aloisi and Elisabetta Tozzi and Raffaella Cusmai and Federico Vigevano and Francesco Chiarelli and Paolo Curatolo",
year = "2008",
month = "1",
doi = "10.1111/j.1469-8749.2007.02009.x",
language = "English",
volume = "50",
pages = "29--32",
journal = "Developmental Medicine and Child Neurology",
issn = "0012-1622",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Levetiracetam in juvenile myoclonic epilepsy

T2 - Long-term efficacy in newly diagnosed adolescents

AU - Verrotti, Alberto

AU - Cerminara, Caterina

AU - Coppola, Giangennaro

AU - Franzoni, Emilio

AU - Parisi, Pasquale

AU - Iannetti, Paola

AU - Aloisi, Paolo

AU - Tozzi, Elisabetta

AU - Cusmai, Raffaella

AU - Vigevano, Federico

AU - Chiarelli, Francesco

AU - Curatolo, Paolo

PY - 2008/1

Y1 - 2008/1

N2 - The aim of this study was to evaluate the efficacy and tolerability of levetiracetam (LEV) monotherapy in juvenile myoclonic epilepsy (JME). The study group consisted of 32 patients with epilepsy (20 males, 12 females) with a mean age of 13 years 3 months (SD 7y 11mo) at seizure onset. LEV was administered as the first drug; all patients were followed up at 6 and 12 months. The dose that achieved seizure control ranged from 1000 to 2500mg/daily. At 6-month evaluation: 15 patients were seizure free; 14 patients were responders (>50% reduction in seizures); and three patients had marginal effects (

AB - The aim of this study was to evaluate the efficacy and tolerability of levetiracetam (LEV) monotherapy in juvenile myoclonic epilepsy (JME). The study group consisted of 32 patients with epilepsy (20 males, 12 females) with a mean age of 13 years 3 months (SD 7y 11mo) at seizure onset. LEV was administered as the first drug; all patients were followed up at 6 and 12 months. The dose that achieved seizure control ranged from 1000 to 2500mg/daily. At 6-month evaluation: 15 patients were seizure free; 14 patients were responders (>50% reduction in seizures); and three patients had marginal effects (

UR - http://www.scopus.com/inward/record.url?scp=37449014099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37449014099&partnerID=8YFLogxK

U2 - 10.1111/j.1469-8749.2007.02009.x

DO - 10.1111/j.1469-8749.2007.02009.x

M3 - Article

C2 - 18173626

AN - SCOPUS:37449014099

VL - 50

SP - 29

EP - 32

JO - Developmental Medicine and Child Neurology

JF - Developmental Medicine and Child Neurology

SN - 0012-1622

IS - 1

ER -